New Ph III results bode well for tiotropium in previously treated asthma
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's long-acting bronchodilator tiotropium delivered once-daily with the Respimat inhaler showed statistically significant improvements in lung function and reduced the incidence of asthma exacerbations in the first two of several Phase III studies under the company's UniTinA-asthma programme.